
    
      The purpose of this multi center, single arm study is to demonstrate the safety and
      performance of the Second Generation Anti-Microbial (InterGard Synergy) vascular graft in the
      treatment of aneurismal and occlusive diseases of the abdominal aorta.

      The primary endpoint is the assessment of primary and secondary graft patency. The secondary
      endpoints were the assessment of adverse events and the assessment of triclosan and silver
      contents in the serum over the time.
    
  